Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy
Journal for ImmunoTherapy of Cancer · 2023-01 · 11 (1) · e005937
DOI: 10.1136/jitc-2022-005937 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 02.01.2023. Verfasst von Jie Dai und 23 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Ca…. Hauptthemen laut MEDLINE: Melanoma, Esophageal Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Natural Science Foundation, Beijing Municipal Administration of Hospitals’ Ascent Plan, Beijing Medical Award Foundation.
Abstract (Originalsprache)
Background
Accumulating data suggest that mucosal melanoma, well known for its poor response to immune checkpoint blockade (ICB) and abysmal prognosis, is a heterogeneous subtype of melanoma with distinct genomic and clinical characteristics between different anatomic locations of the primary lesions. Primary malignant melanoma of the esophagus (PMME) is a rare, highly aggressive disease with a poorer prognosis compared with that of non-esophageal mucosal melanoma (NEMM). In this study, we retrospectively analyzed the efficacy of anti-programmed death (PD)-1 in patients with PMME and explored its molecular basis.
Methods
The response and survival of patients with PMME and NEMM under anti-PD-1 monotherapy were retrospectively analyzed. To explore the molecular mechanisms of the difference in therapeutic efficacy between PMME and NEMM, we performed genomic analysis, bulk RNA sequencing, and multiplex immunohistochemistry staining.
Results
We found that PMME (n=28) responded better to anti-PD-1 treatment than NEMM (n=64), with a significantly higher objective response rate (33.3% (95% CI 14.3% to 52.3%) vs 6.6% (95% CI 0.2% to 12.9%)) and disease control rate (74.1% (95% CI 56.4% to 91.7%) vs 37.7% (95% CI 25.2% to 50.2%)). Genomic sequencing analysis revealed that the genomic aberration landscape of PMME predominated in classical cancer driver genes, with approximately half of PMME cases harboring mutations in BRAF , N/KRAS , and NF1 . In contrast, most NEMM cases were triple wild-type. Transcriptome analysis revealed that, compared with NEMM, PMME displayed more significant proliferation and inflammatory features with higher expression of genes related to antigen presentation and differentiation, and a less immunosuppressive signature with lower expression of inhibitory immune checkpoints and dedifferentiation-related genes. The multiplex immunohistochemical analysis also demonstrated higher CD8 + T-cell infiltration in PMME than in NEMM.
Conclusions
PMME is an outlier of mucosal melanoma showing a malicious phenotype but a particularly high response rate to ICB because of its distinct molecular characteristics. Patient stratification based on anatomic origin can facilitate clinical decision-making in patients with mucosal melanoma following the verification of our results in future prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China.
- State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
- GenePlus- Shenzhen Clinical Laboratory, Shenzhen, China.
- Department of Medical Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
- Geneplus-Beijing, Beijing, China.
ORCID-Profile: Jie Dai, Xue Bai, Chuanliang Cui, Xinan Sheng, Bin Lian, Bixia Tang, Li Zhou
Förderung
- Beijing Natural Science Foundation
- Beijing Municipal Administration of Hospitals’ Ascent Plan
- Beijing Medical Award Foundation
- National Natural Science Foundation of China
Zitieren
APA
Dai, J., Bai, X., Gao, X., Tang, L., Chen, Y., Sun, L., Wei, X., Li, C., Qi, Z., Kong, Y., Cui, C., Chi, Z., Sheng, X., Xu, Z., Lian, B., Li, S., Yan, X., Tang, B., Zhou, L., …, & Si, L. (2023). Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy. Journal for ImmunoTherapy of Cancer, 11(1), e005937. https://doi.org/10.1136/jitc-2022-005937
Vancouver
Dai J, Bai X, Gao X, Tang L, Chen Y, Sun L, et al. Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy. Journal for ImmunoTherapy of Cancer. 2023;11(1):e005937. doi:10.1136/jitc-2022-005937
BibTeX
@article{Dai2023,
author = {Dai, Jie and Bai, Xue and Gao, Xuan and Tang, Lirui and Chen, Yu and Sun, Linzi and Wei, Xiaoting and Li, Caili and Qi, Zhonghui and Kong, Yan and Cui, Chuanliang and Chi, Zhihong and Sheng, Xinan and Xu, Zelong and Lian, Bin and Li, Siming and Yan, Xieqiao and Tang, Bixia and Zhou, Li and Wang, Xuan and Xia, Xuefeng and Guo, Jun and Mao, Lili and Si, Lu},
title = {Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {1},
pages = {e005937},
doi = {10.1136/jitc-2022-005937}
}
EUVIMED